LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020

By LabMedica International staff writers
Posted on 06 Feb 2020
Print article
Image: The PCR ONE system (Photo courtesy of Scope Fluidics Group)
Image: The PCR ONE system (Photo courtesy of Scope Fluidics Group)
Scope Fluidics Group (Warsaw, Poland) presented its new PCR|ONE system at MEDLAB Middle East, one of the world’s major events in the field of medical diagnostics that was held in Dubai World Trade Center and attended by thousands of visitors from over 135 countries.

New technology and the latest innovations in laboratory medicine were the main focus of the inaugural Transformation Talks, taking place at MEDLAB Middle East held from February 3-6, 2020. In line with the show’s theme of Transforming tomorrow’s diagnostics, a range of new features were added to the 2020 edition of MEDLAB Middle East, including the Transformation Hub, where manufacturers had the opportunity to pitch their healthcare solutions to thousands of distributors.

Scope Fluidics introduced the PCR|ONE system to the participants of Transformation Talks at this year’s MEDLAB. The PCR|ONE is a 15-minute Point-Of-Care PCR for screening and syndromic testing that offers the world’s most rapid detection of bacteria and viruses – up to 20 different pathogens and drug resistance genes. The system is designed to analyze samples taken from a single patient in as little as 15 minutes, while its compact size makes it suitable for use in almost any medical practice or hospital admissions room.

“Technology is truly transforming medical diagnostics and healthcare and we are excited to take part in this process and contribute to faster and better access to information. This access to information is key to effective treatment because information allows for better formation of decisions. It saves lives and increases the comfort of patients and, ultimately, helps to reduce healthcare costs,” said Prof. Piotr Garstecki, CEO and Founder of Scope Fluidics Group. “The search and destroy policy urgently requires a rapid, accessible, and affordable diagnostic method than can be used in various settings. We believe PCR|ONE meets this crucial global need for a single-step method for rapidly and inexpensively identifying MRSA directly from nasal swabs.”

Related Links:
Scope Fluidics Group

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more